弛豫补偿的酰胺质子转移(APT)MRI信号强度与高级别胶质瘤患者的生存和进展相关
这项前瞻性研究纳入26例新诊断高级别胶质瘤(WHO III-IV级)患者,在7.0-T全身扫描仪上行弛豫补偿CEST MRI,采用单变量Cox比例风险回归评估APT、rNOE/NOE、dns-APT及ADC与OS/PFS的关联。弛豫补偿APT信号与OS(HR=3.15,p=0.02)和PFS(HR=1.83,p=0.009)显著相关,dns-APT与PFS关联最强(HR=2.61,p=0.002);在22例IDH野生型胶质母细胞瘤同质子队列中结果仍成立。年龄和治疗方式亦与OS显著相关。
要点
- 弛豫补偿APT信号强度与高级别胶质瘤患者总生存(HR=3.15,p=0.02)和无进展生存(HR=1.83,p=0.009)显著相关。
- dns-APT指标与无进展生存的关联最强(HR=2.61,p=0.002)。
- 在22例IDH野生型胶质母细胞瘤同质子队列中,弛豫补偿APT对比的结果仍然成立。
核心结论
- 弛豫补偿APT MRI信号强度与新诊断、未经治疗的胶质瘤患者的总生存和无进展生存相关,未来可能有助于个体化治疗和疗效监测。
研究设计与样本
- 前瞻性IRB批准研究,纳入26例新诊断高级别胶质瘤(WHO III-IV级)患者,在7.0-T全身扫描仪上行CEST MRI,采用单变量Cox比例风险回归评估弛豫补偿CEST MRI(APT、rNOE/NOE、dns-APT)和扩散加权成像(表观扩散系数)与OS/PFS的关联。
诊断标准与关键数值
- 弛豫补偿APT与OS相关:HR=3.15,p=0.02。
- 弛豫补偿APT与PFS相关:HR=1.83,p=0.009。
- dns-APT与PFS关联最强:HR=2.61,p=0.002。
- 在22例IDH野生型胶质母细胞瘤同质子队列中,弛豫补偿APT对比的结果仍然成立。
- 临床参数中,年龄与OS相关(HR=1.1,p=0.001),治疗方式与OS相关(HR=3.68,p=0.026),年龄还与PFS相关(HR=1.04,p=0.048)。
临床应用与阅片要点
- 作者认为弛豫补偿APT MRI信号强度可能有助于未来个体化治疗和疗效监测。
- 作者指出弛豫补偿可增强APT MRI在肿瘤中的信息价值。
- 作者提出CEST MRI可能作为无创生物标志物用于预测预后和个体化治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to investigate the association of relaxation-compensated chemical exchange saturation transfer (CEST) MRI with overall survival (OS) and progression-free survival (PFS) in newly diagnosed high-grade glioma (HGG) patients.
METHODS: Twenty-six patients with newly diagnosed high-grade glioma (WHO grades III-IV) were included in this prospective IRB-approved study. CEST MRI was performed on a 7.0-T whole-body scanner. Association of patient OS/PFS with relaxation-compensated CEST MRI (amide proton transfer (APT), relayed nuclear Overhauser effect (rNOE)/NOE, downfield-rNOE-suppressed APT (dns-APT)) and diffusion-weighted imaging (apparent diffusion coefficient) were assessed using the univariate Cox proportional hazards regression model. Hazard ratios (HRs) and corresponding 95% confidence intervals were calculated. Furthermore, OS/PFS association with clinical parameters (age, gender, O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status, and therapy: biopsy + radio-chemotherapy vs. debulking surgery + radio-chemotherapy) were tested accordingly.
RESULTS: Relaxation-compensated APT MRI was significantly correlated with patient OS (HR = 3.15, p = 0.02) and PFS (HR = 1.83, p = 0.009). The strongest association with PFS was found for the dns-APT metric (HR = 2.61, p = 0.002). These results still stand for the relaxation-compensated APT contrasts in a homogenous subcohort of n = 22 glioblastoma patients with isocitrate dehydrogenase (IDH) wild-type status. Among the tested clinical parameters, patient age (HR = 1.1, p = 0.001) and therapy (HR = 3.68, p = 0.026) were significant for OS; age additionally for PFS (HR = 1.04, p = 0.048).
CONCLUSION: Relaxation-compensated APT MRI signal intensity is associated with overall survival and progression-free survival in newly diagnosed, previously untreated glioma patients and may, therefore, help to customize treatment and response monitoring in the future.
KEY POINTS: • Amide proton transfer (APT) MRI signal intensity is associated with overall survival and progression in glioma patients. • Relaxation compensation enhances the information value of APT MRI in tumors. • Chemical exchange saturation transfer (CEST) MRI may serve as a non-invasive biomarker to predict prognosis and customize treatment.
引用
- Paech D, Dreher C, Regnery S, et al. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol. 2019. PMID: 30809720. doi:10.1007/s00330-019-06066-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。